Chemotherapy of soft tissue sarcoma: A clinical evaluation of treatment over ten years

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Starkhammar Hans 1948 ) > Chemotherapy of sof...

Wall, Najme,1963-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US (författare)

Chemotherapy of soft tissue sarcoma : A clinical evaluation of treatment over ten years

Artikel/kapitelEngelska2003

Förlag, utgivningsår, omfång ...

2009-07-08
Informa UK Limited,2003
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:liu-25374
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-25374URI
https://doi.org/10.1080/0891060310002249DOI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

The aim of the study was to evaluate the effect of palliative chemotherapy on soft tissue sarcomas given outside controlled trials. Therapy and response rates of 77 patients with non-resectable sarcoma treated with different regimens between 1991 and 2000 were reviewed. Thirty-six patients were treated with first-line chemotherapy comprising cyclophosphamide+vincristine+doxorubicin+dacarbazine (CYVADIC), with a response rate of 28% (median response duration 5.5 months). Etoposide and ifosfamide (IVP, or VIG, which also includes granulocyte colony-stimulating factor (G-CSF)) were used in the treatment of 18 patients. The response rate was 22% (median response duration 4.5 months), Nineteen patients were treated with doxorubicin+ifosfamide and one patient responded. Four patients received other first-line treatments. Thirty-eight patients were given second-line chemotherapy and 4 (10%) patients responded. Thirteen patients were given third-line treatment and 5 patients received fourth-line treatment, but without any response. Disease progression was the dominant reason for discontinuation of therapy. The response rate in the present study was lower than the best published results, probably due to the fact that our soft tissue sarcoma patient material was unselected. Treatment with CYVADIC yields at least as high a response rate as the more recently described doxorubicin+ifosfamide combination, but third- and fourth-line therapy is not beneficial. Clinical trials with more active drugs are needed, as are more predictive and prognostic tests and a better selection of patient groups suited for different treatment options for soft tissue sarcomas.

Ämnesord och genrebeteckningar

MEDICINE
MEDICIN

Biuppslag (personer, institutioner, konferenser, titlar ...)

Starkhammar, Hans,1948-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)hanst87 (författare)
Linköpings universitetHälsouniversitetet (creator_code:org_t)

Sammanhörande titlar

Ingår i:Acta Oncologica: Informa UK Limited42:1, s. 55-610284-186X1651-226X

Internetlänk

Hitta via bibliotek

Acta Oncologica (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Wall, Najme, 196 ...; Starkhammar, Han ...

Artiklar i publikationen: Acta Oncologica

Av lärosätet: Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se